Browsing: NVONYSE
Peter HansenNovo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people…
aprott/iStock via Getty ImagesRivaling Eli Lilly’s (NYSE:LLY) direct-to-consumer platform LillyDirect, which made its market debut last year, Novo Nordisk (NVO)…
Victor GolmerMakers of copycat versions of Novo Nordisk’s (NVO) popular weight-loss drug semaglutide, also known as Ozempic and Wegovy, are…
Andrew Harnik/Getty Images NewsObesity drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) have found themselves in two contrasting positions as…
Carolina RudahA new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and…
wingedwolf The Centers for Medicare and Medicaid Services (CMS) on Friday announced 15 additional Medicare Part D drugs selected for…
Terminator3D/iStock via Getty ImagesBlockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of…
hapabapa/iStock Editorial via Getty ImagesNovo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as…
CRNovo Nordisk (NVO) and Eli Lilly (LLY), the undisputed leaders in the global obesity drug market, saw their stocks heading…
hapabapa/iStock Editorial via Getty ImagesNovo Nordisk’s (NVO) next-gen weight loss therapy, CagriSema, caused up to ~23% of weight loss compared…